| Title |
Clinical Study of Anti-BCMA and Anti-CD19 Nanobody CAR-T Cells in the Treatment of Refractory or Relapsed Malignancies -- A Single-Center, Single-Arm, Open-Label Clinical Study |
| Description |
Summary Tables of Clinical Efficacy Evaluation and Adverse Events in the treatment of refractory or relapsed multiple myeloma and B cell-acute lymphoblastic leukemia |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Clinical information |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA014881 |
| Release Date |
2024-12-31 |
| Submitter |
Jishuai Zhang (zhangjs@pregene.com) |
| Organization |
Shenzhen Prikin Biopharmaceutical Co., Ltd |
| Submission Date |
2023-02-10 |